Retinopathy of Prematurity — International Classification (ICROP3)
International Classification of Retinopathy of Prematurity 3rd revision (Chiang 2021). Combines Zone (I most posterior, III peripheral nasal), Stage (1–5), and Plus disease. Used to time treatment in screened preterm neonates.
Score interpretation
→ Continue UK ROP screening protocol per RCPCH/BAPM/RCOphth: weekly–fortnightly fundus exams until vascularisation reaches Zone III or 36 weeks PMA / discharge — whichever later.
→ Weekly screening. Treatment not yet indicated. Anticipate spontaneous regression but be ready to escalate.
→ Treatment within 48–72 hours: laser photocoagulation (gold standard) or intravitreal anti-VEGF (ranibizumab/bevacizumab — NICE TA855 ranibizumab). Joint neonatology + ophthalmology decision. Long-term follow-up for myopia and late detachment.
→ Urgent paediatric vitreoretinal referral. Lens-sparing vitrectomy ± scleral buckle (Stage 4A/4B) or vitrectomy with capsulectomy (Stage 5) — outcomes guarded for Stage 5. Lifelong follow-up; visual rehabilitation; family support.
Interpretation bands for the ROP. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Ranibizumab · Anti-VEGF (intravitreal injection)
- Bevacizumab (Intravitreal) · Anti-VEGF (Vascular Endothelial Growth Factor Inhibitor)
- Aflibercept 2mg/0.05mL Intravitreal Injection (Eylea) · Anti-VEGF agent (intravitreal)
- Faricimab (Intravitreal) · Anti-VEGF and Anti-Ang-2 — Bispecific Monoclonal Antibody
- Brolucizumab (Intravitreal) · Anti-VEGF — Single-chain Antibody Fragment (scFv)
- Pegaptanib Sodium · Anti-VEGF (RNA Aptamer) — Neovascular AMD
- Acute Red Eye / Vision Loss Screen · RCOphth 2020; NICE CKS
- Idiopathic Intracranial Hypertension · ABN; consensus 2018
- Acute Red Eye Assessment · RCOphth / AAO
- Acute Angle Closure Glaucoma · RCOphth / EGS Guidelines
- Retinal Detachment · RCOphth Guidelines / EURETINA
- Diabetic Retinopathy — Screening and Management · NICE NG28 2016 / NHS DES Programme
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.